Drug Profile
Research programme: anti-cancer antibodies - Eureka Therapeutics/Boehringer Ingelheim
Alternative Names: TCR-mimicking (TCRm) antibodies - Eureka TherapeuticsLatest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Eureka Therapeutics
- Developer Boehringer Ingelheim; Eureka Therapeutics
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Cancer in Germany (Parenteral)
- 28 Jun 2019 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 17 Jul 2018 Boehringer Ingelheim exercises its option to license TCR-mimicking (TCRm) antibodies for Cancer